FDA warned www.usmedschoice.com for selling unapproved and misbranded opioids, benzodiazepines, and stimulants online without prescriptions.
What happened
FDA reviewed the website www.usmedschoice.com and found it offered opioids, benzodiazepines, and Schedule II stimulants for sale to U.S. consumers. FDA said the products were unapproved new drugs and misbranded because they lacked FDA approval and adequate directions, and some were offered without a prescription.
What FDA found
The website offered drugs that are not approved by FDA for sale in the U.S.
FD&C Act sections 301(d) and 505(a) [21 U.S.C. §§ 331(d), 355(a)]The website offered prescription drugs for sale without requiring a prescription.
FD&C Act sections 503(b)(1) and 301(k) [21 U.S.C. §§ 353(b)(1), 331(k)]The drug labeling did not include adequate directions for safe use by a layperson.
FD&C Act section 502(f)(1) [21 U.S.C. § 352(f)(1)]The website caused misbranded drugs to be introduced into interstate commerce.
FD&C Act section 301(a) [21 U.S.C. § 331(a)]
What FDA wants
FDA requests that www.usmedschoice.com stop offering any unapproved and misbranded drugs for sale to U.S. consumers. The company must respond in writing within 15 working days with corrective steps and documentation, or explain why it believes the products comply.
Who should pay attention
- online pharmacies and website operators selling prescription drugs
- companies that fulfill or advertise opioids, benzodiazepines, or stimulants
- telehealth and e-commerce platforms handling prescription drug sales
This is a summary. Read the original letter on fda.gov.